Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genomic Valley Biotech's Revenue for the
three
months ended in Jun. 2026 was ₹0.38 Mil. Genomic Valley Biotech's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹23.18 Mil.
Hence, Genomic Valley Biotech's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.02.
Genomic Valley Biotech (BOM:539206) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Genomic Valley Biotech Receivables Turnover Related Terms
Genomic Valley Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Genomic Valley Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539206 vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomic Valley Biotech (BOM:539206) has a Receivables Turnover of 0.02 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genomic Valley Biotech and its competitors. According to the industry distribution chart, Genomic Valley Biotech ranks #841 out of 853 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Genomic Valley Biotech's Receivables Turnover too high?
Genomic Valley Biotech's current Receivables Turnover is 0.02. The Biotechnology industry median Receivables Turnover is 5.28. Genomic Valley Biotech's value of 0.02 is 99.6% below this industry median. Based on the distribution chart, Genomic Valley Biotech ranks #841 out of 853 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #841 out of 853 companies for Receivables Turnover. This places Genomic Valley Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.28. Genomic Valley Biotech's value of 0.02 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomic Valley Biotech's current Receivables Turnover of 0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genomic Valley Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current Receivables Turnover is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.22, compared to a current price of ₹30.20 — trading 169.2% above its estimated fair value. The current Receivables Turnover is 0.02 and 99.6% below the Biotechnology industry median of 5.28. Genomic Valley Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Receivables Turnover is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹30.20 is trading 169.2% above its estimated GF Value™ of ₹11.22.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
Receivables Turnover: 0.02
GF Value™: ₹11.22 vs. price of ₹30.20 (169.2% above fair value)
Industry Position: 99.6% below the Biotechnology median (#841 of 853)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
58GF Score
Get the complete analysis for BOM:539206
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
